Monashee Investment Management LLC Makes New $1.92 Million Investment in SAB Biotherapeutics, Inc. $SABS

Monashee Investment Management LLC acquired a new position in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the first quarter, HoldingsChannel reports. The firm acquired 500,000 shares of the company’s stock, valued at approximately $1,915,000.

A number of other institutional investors have also modified their holdings of SABS. Vivo Capital LLC acquired a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $22,954,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics during the third quarter valued at approximately $8,847,000. Woodline Partners LP acquired a new position in SAB Biotherapeutics during the third quarter valued at approximately $5,730,000. Spruce Street Capital LP purchased a new stake in SAB Biotherapeutics during the fourth quarter worth approximately $8,222,000. Finally, Perceptive Advisors LLC purchased a new stake in SAB Biotherapeutics during the fourth quarter worth approximately $3,004,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on SABS shares. Chardan Capital lifted their target price on shares of SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Wednesday, July 8th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $13.00 target price on shares of SAB Biotherapeutics in a research report on Monday, May 11th. Finally, Barclays assumed coverage on SAB Biotherapeutics in a research report on Wednesday, June 24th. They issued an “overweight” rating and a $13.00 target price for the company. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, SAB Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

SAB Biotherapeutics Price Performance

Shares of NASDAQ SABS opened at $3.58 on Thursday. SAB Biotherapeutics, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $5.15. The business has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $3.85. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The firm has a market cap of $273.73 million, a PE ratio of -1.70 and a beta of 0.52.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Sell-side analysts expect that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.